



Financial Tear Sheet

Corporate Profile

Cambrex Corporation is a custom development and manufacturing organization that specializes in products and services that accelerate the development and commercialization of small molecule therapeutics.

We offer APIs, advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals.

Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage forms.

Primary IR Contact

Stephanie LaFiura
Investor Relations Associate
Phone: 201-804-3037
Fax: 201-804-9852
E-mail:
stephanie.lafiura@cambrex.com

Stock Performance

Symbol CBM (Common Stock)

Exchange NYSE (US Dollar)

Price \$48.00

Change (%) ▲ 0.10 (0.21%)

Volume 72,401

Data as of May 22, 2018 12:20 p.m. ET

Management

Steven M. Klosk
President and Chief
Executive Officer

Shawn P. Cavanagh
Executive Vice President and
Chief Operating Officer

Samantha M. Hanley
Vice President, General
Counsel and Secretary

Gregory P. Sargen
Executive Vice President,
Corporate Development and
Strategy

Tom Vadaketh
Executive Vice President and
Chief Financial Officer

Recent Headlines & Events

There are currently no events scheduled.

Date	Title
May 15, 2018	Cambrex Completes Pilot Plant Expansion at its High Point, NC Facility
May 03, 2018	Cambrex Reports First Quarter 2018 Financial Results
April 26, 2018	Cambrex to Announce First Quarter 2018 Financial Results on May 3, 2018

SEC Filings

Filing Date	Form
May 09, 2018	4
May 09, 2018	4
May 03, 2018	10-Q
May 03, 2018	8-K

Data provided by Nasdaq. Minimum 15 minutes delayed.